SOURCE: OctoPlus

May 16, 2007 02:10 ET

OCTOPLUS TO PRESENT AT SNS SMALL & MID CAP SEMINAR

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- May 16, 2007 -- OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that its Chief Business Officer will present next week at the SNS Small & Mid Cap Seminar in Maarssen, the Netherlands.

Gerben Moolhuizen, Chief Business Officer, will present on Thursday, 24 May at 13.15 AM CEST.

About OctoPlus

OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.

OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.

OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Press release in PDF: http://hugin.info/137076/R/1127076/209403.pdf

Contact Information

  • For further information, please contact:
    Rianne Roukema
    Corporate Communications
    +31 (71) 524 4044